AQD Life Sciences has negotiated an option agreement with Drexel University for breast cancer surgical margin assessment technology - a low-cost near-infrared (NIR) aqueous quantum dots molecular probe-based imaging tool to help surgeons determine intraoperatively if the surgical margin is clear of cancer. Together with Drexel, AQD Life Sciences (AQDLS) has created a cancer-specific molecular probe consisting of patented near infrared (NIR) CdPbS aqueous quantum dots (AQDs) conjugated to anti-Tn antigen antibody (Ab). The firm is addressing develop a prototype NIR imaging system specifically tailored to the optical characteristics of the cancer- specific, NIR Tn-AQDs molecular probe,
